tiprankstipranks
Pfizer (GB:0Q1N)
LSE:0Q1N
UK Market
0Q1N
Pfizer
RESEARCH TOOLSreports

Pfizer (0Q1N) Share Forecast & Price Target

36 Followers
See the Price Targets and Ratings of:

0Q1N Analyst Ratings

Moderate Buy
23Ratings
Moderate Buy
8 Buy
13 Hold
2 Sell
Based on 23 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0Q1N Stock 12 Month Forecast

Average Price Target

$29.02
▲(6.81% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is $29.02 with a high forecast of $36.00 and a low forecast of $25.00. The average price target represents a 6.81% change from the last price of $27.17.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","25":"$25","29":"$29","33":"$33","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.02,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,25,29,33,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.39,28.975384615384616,29.560769230769232,30.146153846153847,30.731538461538463,31.31692307692308,31.902307692307694,32.487692307692306,33.073076923076925,33.65846153846154,34.24384615384616,34.82923076923077,35.41461538461539,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.39,28.43846153846154,28.486923076923077,28.535384615384615,28.583846153846153,28.63230769230769,28.68076923076923,28.72923076923077,28.77769230769231,28.826153846153847,28.874615384615385,28.923076923076923,28.97153846153846,{"y":29.02,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.39,28.12923076923077,27.86846153846154,27.607692307692307,27.346923076923076,27.086153846153845,26.825384615384614,26.564615384615387,26.303846153846155,26.043076923076924,25.782307692307693,25.521538461538462,25.26076923076923,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.269,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.453,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.172,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 57, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.797,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.641,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.848,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.418,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.875,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.552,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.21,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$36.00Average Price Target$29.02Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on GB:0Q1N
Trung Huynh
RBC Capital
RBC Capital
$25
Sell
-7.99%
Downside
Reiterated
04/07/26
RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
Bernstein Analyst forecast on GB:0Q1N
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
04/03/26
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (NASDAQ: UPB) and Pfizer (NYSE: PFE)
Wells Fargo Analyst forecast on GB:0Q1N
Mohit Bansal
Wells Fargo
Wells Fargo
$28
Hold
3.05%
Upside
Assigned
04/02/26
Wells Fargo Remains a Hold on Pfizer (PFE)
Erste Group Analyst forecast on GB:0Q1N
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Erste Group Remains a Hold on Pfizer (PFE)
Citi Analyst forecast on GB:0Q1N
Geoff Meacham
Citi
Citi
$26
Hold
-4.31%
Downside
Reiterated
03/24/26
Citi Remains a Hold on Pfizer (PFE)
Guggenheim Analyst forecast on GB:0Q1N
Vamil Divan
Guggenheim
Guggenheim
$35→$36
Buy
32.50%
Upside
Reiterated
03/24/26
Pfizer price target raised to $36 from $35 at GuggenheimPfizer price target raised to $36 from $35 at Guggenheim
Jefferies Analyst forecast on GB:0Q1N
Akash Tewari
Jefferies
Jefferies
$34
Buy
25.14%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Idexx Laboratories (NASDAQ: IDXX)
TD Cowen Analyst forecast on GB:0Q1N
Steve Scala
TD Cowen
TD Cowen
$30
Hold
10.42%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Pfizer (NYSE: PFE) and Wave Life Sciences (NASDAQ: WVE)
HSBC Analyst forecast on GB:0Q1N
Rajesh Kumar
HSBC
HSBC
$29→$32
Buy
17.78%
Upside
Reiterated
03/17/26
Pfizer price target raised to $32 from $29 at HSBCPfizer price target raised to $32 from $29 at HSBC
Berenberg Bank Analyst forecast on GB:0Q1N
Kerry Holford
Berenberg Bank
Berenberg Bank
$25
Hold
-7.99%
Downside
Reiterated
03/11/26
Pfizer (PFE) Gets a Hold from Berenberg Bank
Scotiabank Analyst forecast on GB:0Q1N
Louise Chen
Scotiabank
Scotiabank
$30
Buy
10.42%
Upside
Reiterated
03/10/26
Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
UBS Analyst forecast on GB:0Q1N
Michael Yee
UBS
UBS
$25
Hold
-7.99%
Downside
Reiterated
03/10/26
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI), Cullinan Management (NASDAQ: CGEM) and Pfizer (NYSE: PFE)
Argus Research Analyst forecast on GB:0Q1N
David Toung
Argus Research
Argus Research
$35
Buy
28.82%
Upside
Upgraded
03/02/26
Pfizer upgraded to Buy from Hold at ArgusPfizer upgraded to Buy from Hold at Argus
Evercore ISI Analyst forecast on GB:0Q1N
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
02/25/26
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)
Goldman Sachs Analyst forecast on GB:0Q1N
Asad Haider
Goldman Sachs
Goldman Sachs
$26
Hold
-4.31%
Downside
Reiterated
02/19/26
Pfizer (PFE) Gets a Hold from Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on GB:0Q1N
Trung Huynh
RBC Capital
RBC Capital
$25
Sell
-7.99%
Downside
Reiterated
04/07/26
RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)
Bernstein Analyst forecast on GB:0Q1N
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
04/03/26
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (NASDAQ: UPB) and Pfizer (NYSE: PFE)
Wells Fargo Analyst forecast on GB:0Q1N
Mohit Bansal
Wells Fargo
Wells Fargo
$28
Hold
3.05%
Upside
Assigned
04/02/26
Wells Fargo Remains a Hold on Pfizer (PFE)
Erste Group Analyst forecast on GB:0Q1N
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/02/26
Erste Group Remains a Hold on Pfizer (PFE)
Citi Analyst forecast on GB:0Q1N
Geoff Meacham
Citi
Citi
$26
Hold
-4.31%
Downside
Reiterated
03/24/26
Citi Remains a Hold on Pfizer (PFE)
Guggenheim Analyst forecast on GB:0Q1N
Vamil Divan
Guggenheim
Guggenheim
$35→$36
Buy
32.50%
Upside
Reiterated
03/24/26
Pfizer price target raised to $36 from $35 at GuggenheimPfizer price target raised to $36 from $35 at Guggenheim
Jefferies Analyst forecast on GB:0Q1N
Akash Tewari
Jefferies
Jefferies
$34
Buy
25.14%
Upside
Reiterated
03/24/26
Analysts Conflicted on These Healthcare Names: Pfizer (NYSE: PFE) and Idexx Laboratories (NASDAQ: IDXX)
TD Cowen Analyst forecast on GB:0Q1N
Steve Scala
TD Cowen
TD Cowen
$30
Hold
10.42%
Upside
Reiterated
03/24/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Pfizer (NYSE: PFE) and Wave Life Sciences (NASDAQ: WVE)
HSBC Analyst forecast on GB:0Q1N
Rajesh Kumar
HSBC
HSBC
$29→$32
Buy
17.78%
Upside
Reiterated
03/17/26
Pfizer price target raised to $32 from $29 at HSBCPfizer price target raised to $32 from $29 at HSBC
Berenberg Bank Analyst forecast on GB:0Q1N
Kerry Holford
Berenberg Bank
Berenberg Bank
$25
Hold
-7.99%
Downside
Reiterated
03/11/26
Pfizer (PFE) Gets a Hold from Berenberg Bank
Scotiabank Analyst forecast on GB:0Q1N
Louise Chen
Scotiabank
Scotiabank
$30
Buy
10.42%
Upside
Reiterated
03/10/26
Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
UBS Analyst forecast on GB:0Q1N
Michael Yee
UBS
UBS
$25
Hold
-7.99%
Downside
Reiterated
03/10/26
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI), Cullinan Management (NASDAQ: CGEM) and Pfizer (NYSE: PFE)
Argus Research Analyst forecast on GB:0Q1N
David Toung
Argus Research
Argus Research
$35
Buy
28.82%
Upside
Upgraded
03/02/26
Pfizer upgraded to Buy from Hold at ArgusPfizer upgraded to Buy from Hold at Argus
Evercore ISI Analyst forecast on GB:0Q1N
Umer Raffat
Evercore ISI
Evercore ISI
―
Buy
―
Reiterated
02/25/26
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)
Goldman Sachs Analyst forecast on GB:0Q1N
Asad Haider
Goldman Sachs
Goldman Sachs
$26
Hold
-4.31%
Downside
Reiterated
02/19/26
Pfizer (PFE) Gets a Hold from Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

3 Months
xxx
Success Rate
25/36 ratings generated profit
69%
Average Return
+2.87%
reiterated a xxx
 rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 69.44% of your transactions generating a profit, with an average return of +2.87% per trade.
1 Year
Vamil DivanGuggenheim
Success Rate
28/36 ratings generated profit
78%
Average Return
+6.69%
reiterated a buy rating 16 days ago
Copying Vamil Divan's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +6.69% per trade.
2 Years
xxx
Success Rate
17/20 ratings generated profit
85%
Average Return
+8.37%
reiterated a xxx
 rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 85.00% of your transactions generating a profit, with an average return of +8.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q1N Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
35
19
25
20
19
Hold
41
37
40
35
27
Sell
0
0
2
2
2
Strong Sell
0
0
0
0
0
total
76
56
67
57
48
In the current month, 0Q1N has received 19 Buy Ratings, 27 Hold Ratings, and 2 Sell Ratings. 0Q1N average Analyst price target in the past 3 months is 29.02.
Each month's total comprises the sum of three months' worth of ratings.

0Q1N Financial Forecast

0Q1N Earnings Forecast

Next quarter’s earnings estimate for 0Q1N is $0.73 with a range of $0.64 to $0.92. The previous quarter’s EPS was $0.66. 0Q1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0Q1N has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0Q1N is $0.73 with a range of $0.64 to $0.92. The previous quarter’s EPS was $0.66. 0Q1N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 0Q1N has Performed in-line its overall industry.

0Q1N Sales Forecast

Next quarter’s sales forecast for 0Q1N is $13.87B with a range of $13.35B to $14.35B. The previous quarter’s sales results were $17.56B. 0Q1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0Q1N has Performed in-line its overall industry.
Next quarter’s sales forecast for 0Q1N is $13.87B with a range of $13.35B to $14.35B. The previous quarter’s sales results were $17.56B. 0Q1N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 0Q1N has Performed in-line its overall industry.

0Q1N Stock Forecast FAQ

What is GB:0Q1N’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer’s 12-month average price target is 29.02.
    What is GB:0Q1N’s upside potential, based on the analysts’ average price target?
    Pfizer has 6.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pfizer a Buy, Sell or Hold?
          Pfizer has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 13 hold ratings and 2 sell ratings.
            What is Pfizer’s share price target?
            The average share price target for Pfizer is 29.02. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $36.00 ,and the lowest forecast is $25.00. The average share price target represents 6.81% Increase from the current price of $27.17.
              What do analysts say about Pfizer?
              Pfizer’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of Pfizer?
                To buy shares of GB:0Q1N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.